MoonLake earns new Outperform at RBC Capital Markets on lead drug
Source: SeekingAlpha
2025-03-18 11:18:34 ET
More on MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
- MoonLake Immunotherapeutics reports Q4 results
- MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset
- Seeking Alpha’s Quant Rating on MoonLake Immunotherapeutics
- Historical earnings data for MoonLake Immunotherapeutics
Read the full article on Seeking Alpha
For further details see:
MoonLake earns new Outperform at RBC Capital Markets on lead drug
MoonLake Immunotherapeutics
NASDAQ: MLTX
MLTX Trading
0.79% G/L:
$17.255 Last:
279,190 Volume:
$17.14 Open:
MLTX Latest News
MLTX Stock Data
$1,003,283,878
28,454,210
3.61%
24
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zug
